Metformina + Vildagliptina Teva

Metformin Hydrochloride, the active ingredient in Metformina + Vildagliptina Teva, is a biguanide/DPP‑4 inhibitor presented as a tablet for oral use. It is used to improve blood glucose control in adults with type 2 diabetes mellitus.

GNH USA supplies Metformina + Vildagliptina Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Metformina + Vildagliptina is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by elevated blood glucose. The combination targets hyperglycemia through complementary mechanisms that reduce hepatic glucose output and enhance insulin secretion.

- Type 2 diabetes mellitus: lowers fasting plasma glucose levels. - Type 2 diabetes mellitus: reduces glycated hemoglobin (HbA1c) values. - Type 2 diabetes mellitus: diminishes post‑prandial glucose excursions when used with diet and exercise.

The combination may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea - Diarrhea - Abdominal discomfort - Headache - Metallic taste in the mouth - Decreased appetite

Serious or Rare Side Effects: - Lactic acidosis (metformin related) - Severe hypoglycemia (especially when combined with other glucose‑lowering agents) - Acute pancreatitis - Hepatic dysfunction - Severe skin reactions such as Stevens‑Johnson syndrome - Anaphylactic or severe allergic reactions

When prescribing Metformina + Vildagliptina, clinicians should consider several safety aspects.

- Renal function: assess creatinine clearance before initiation and periodically thereafter. - Hepatic impairment: use with caution; monitor liver enzymes. - Risk of lactic acidosis: avoid in patients with conditions predisposing to hypoxia. - Alcohol consumption: advise patients to limit intake to reduce acidosis risk. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Metformina + Vildagliptina may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate renal dysfunction and increase lactic acidosis risk. - Chronic alcohol abuse: heightens risk of metformin‑associated lactic acidosis. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise vildagliptin plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics (especially thiazides): may affect renal clearance of metformin. - Beta‑blockers: can mask symptoms of hypoglycemia. - ACE inhibitors or ARBs: monitor renal function and electrolytes when used together.